MedPath

Examination of the effectiveness of Quasi-particle accelerator (QPA) for fibromyalgia

Not Applicable
Conditions
fibromyalgia
Registration Number
JPRN-UMIN000044620
Lead Sponsor
Tokushima University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
3
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with implantable electronic devices (such as pacemakers) Patients with serious heart disease, kidney disease, liver disease Patients with arterial oxygen saturation <94% without oxygen Patients with severe peripheral neuropathy Persons who have lost temperature sensitivity Patients who cannot express their intention Patients with hypersensitivity, injury or lesions on the skin of the pad area (upper back and lower back) Pregnancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total score of the Japanese version of the Revised Fibromyalgia Impact Questionnaire (JFIQR) before and 4 weeks after the start of QPA treatment
Secondary Outcome Measures
NameTimeMethod
The changes in JFIQR domain (1), (2), (3) and each item before and 4 weeks after the start of QPA treatment
© Copyright 2025. All Rights Reserved by MedPath